Effects of miR-152 on cell growth inhibition, motility suppression and apoptosis induction in hepatocellular carcinoma cells

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 12, 2014, Pages 4969-4976

  Dang, Yi Wu ^a   Zeng, Jing ^a   He, Rong Quan ^a   Rong, Min Hua ^a   Luo, Dian Zhong ^a   Chen, Gang ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cell growth; Hepatocellular carcinoma; miR 152; Motility; TNFRSF6B

Indexed keywords

DECOY RECEPTOR 3; MESSENGER RNA; MICRORNA; MIRN152 MICRORNA, HUMAN; TNFRSF6B PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; CANCER STAGING; CELL MOTION; CELL PROLIFERATION; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GENETICS; HUMAN; LIVER; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR CELL CULTURE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84904621299     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.12.4969     Document Type: Article

References (42)

1. Azizi M, Teimoori-Toolabi L, Arzanani MK, et al (2014). MicroRNA-148b and microRNA-152 reactivate tumor suppressor genes through suppression of DNA methyltransferase-1 gene in pancreatic cancer cell lines. Cancer Biol Ther, 15, 419-27.
2. Braconi C, Huang N, Patel T (2010). MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology, 51, 881-90.
3. Chen G, Luo DZ, Liu L, et al (2006). Hepatic local micro-environmental immune status in hepatocellular carcinoma and cirrhotic tissues. West Indian Med J, 55, 403-8.
4. Chen G, Dang YW, Luo DZ, et al (2008a). Expression of heparanase in hepatocellular carcinoma has prognostic significance: a tissue microarray study. Oncol Res, 17, 183-9.
5. Chen G, Luo D (2008b). Expression of decoy receptor 3 in liver tissue microarrays. Natl Med J India, 21, 275-8.
6. Chen G, Rong M, Luo D (2010a). TNFRSF6B neutralization antibody inhibits proliferation and induces apoptosis in hepatocellular carcinoma cell. Pathol Res Pract, 206, 631-41.
7. Chen G, Kronenberger P, Umelo IA, et al (2010b). Quantification of epidermal growth factor receptor T790M mutant transcripts in lung cancer cells by real-time reverse transcriptase-quantitative polymerase chain reaction. Anal Biochem, 398, 266-8.
8. Chen G, Kronenberger P, Teugels E, et al (2011). Influence of RT-qPCR primer position on EGFR interference efficacy in lung cancer cells. Biol Proced Online, 13, 1-8.
9. Chen G, Kronenberger P, Teugels E, et al (2012). Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med, 10, 28.
10. Chen G, Kronenberger P, Teugels E, et al (2013a). Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents. Biochem Biophys Res Commun, 431, 623-9.
11. Chen G, Noor A, Kronenberger P, et al (2013b). Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib. PLoS One, 8, e59708.
12. Chen G, Umelo IA, Lv S, et al (2013c). miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells. PLoS One, 8, e60317.
13. Chen Y, Song Y, Wang Z, et al (2010c). Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance. J Gastrointest Surg, 14, 1170-9.
14. Chen Y, Song YX, Wang ZN (2013d). The microRNA-148/152 family: multi-faceted players. Molecular cancer, 12, 43.
15. Dang Y, Luo D, Rong M, et al (2013). Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PloS one, 8, e61054.
16. Das S, Foley N, Bryan K, et al. (2010). MicroRNA mediates DNA demethylation events triggered by retinoic acid during neuroblastoma cell differentiation. Cancer Res, 70, 7874-81.
17. Hiroki E, Akahira J, Suzuki F, Nagase S, Ito K, Suzuki T, et al. (2010). Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci, 101, 241-9.
18. Hu L, Chen G, Yu H, Qiu X (2010). Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma. Hepatol Int, 4, 423-32.
19. Huang J, Wang Y, Guo Y, et al (2010). Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology, 52, 60-70.
20. Huang S, Xie Y, Yang P, et al (2014). HCV core protein-induced down-regulation of microRNA-152 promoted aberrant proliferation by regulating Wnt1 in HepG2 Cells. PloS one, 9, e81730.
21. Hunt EA, Goulding AM, Deo SK (2009). Direct detection and quantification of microRNAs. Anal Biochem, 387, 1-12.
22. Karabork A, Kaygusuz G, Ekinci C (2010). The best immunohistochemical panel for differentiating hepatocellular carcinoma from metastatic adenocarcinoma. Pathol Res Pract, 206, 572-7.
23. Kohler CU, Bryk O, Meier S, et al (2013). Analyses in human urothelial cells identify methylation of miR-152, miR-200b and miR-10a genes as candidate bladder cancer biomarkers. Biochemical and biophysical research communications, 438, 48-53.
24. Kudo M (2011). Hepatocellular carcinoma in 2011 and beyond: from the pathogenesis to molecular targeted therapy. Oncology, 81, 1-10.
25. Lichner Z, Fendler A, Saleh C, et al (2013). MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer. Clin Chem, 59, 1595-603.
26. Liu DZ, Ander BP, Tian Y, et al (2012). Integrated analysis of mRNA and microRNA expression in mature neurons, neural progenitor cells and neuroblastoma cells. Gene, 495, 120-7.
27. Mollaie HR, Monavari SH, Arabzadeh SA, et al (2013). RNAi and miRNA in viral infections and cancers. Asian Pacific J Cancer Prev, 14, 7045-56.
28. Papagiannakopoulos T, Kosik KS (2008). MicroRNAs: regulators of oncogenesis and stemness. BMC Med, 6, 15.
29. Rong M, Chen G, Dang Y (2013a). Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro. BMC Cancer, 13, 21.
30. Rong M, He R, Dang Y, et al (2013b). Expression and clinicopathological significance of miR-146a in hepatocellular carcinoma tissues. Ups J Med Sci, 119, 19-24.
31. Song H, Liu Y, Pan J, et al (2013). Expression profile analysis reveals putative prostate cancer-related microRNAs. Genet Mol Res, 12, 4934-43.
32. Song YX, Yue ZY, Wang ZN, et al (2011). MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation. Mol Cancer, 10, 1.
33. Sun J, Lu HQ, Wang X, et al (2013). MicroRNAs in Hepatocellular Carcinoma: Regulation, Function, and Clinical Implications. Sci World J, 2013, 924206.
34. Tsai MC, Spitale RC, Chang HY (2011). Long intergenic noncoding RNAs: new links in cancer progression. Cancer Res, 71, 3-7.
35. Tsuruta T, Kozaki K, Uesugi A, et al (2011). miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res, 71, 6450-62.
36. Woo HH, Laszlo CF, Greco S, et al (2012). Regulation of colony stimulating factor-1 expression and ovarian cancer cell behavior in vitro by miR-128 and miR-152. Mol Cancer, 11, 58.
37. Xiang Y, Ma N, Wang D, et al (2014). MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene, 33, 378-86.
38. Yamazaki K, Masugi Y, Sakamoto M (2011). Molecular pathogenesis of hepatocellular carcinoma: altering transforming growth factor-beta signaling in hepatocarcinogenesis. Dig Dis, 29, 284-8.
39. Yang M, Chen G, Dang Y, Luo D (2010). Significance of decoy receptor 3 in sera of hepatocellular carcinoma patients. Ups J Med Sci, 115, 232-7.
40. Zhang J, Wang R, Ma YY, Chen LQ, Jin BH, Yu H, et al. (2013). Association between single nucleotide polymorphisms in miRNA196a-2 and miRNA146a and susceptibility to hepatocellular carcinoma in a Chinese population. Asian Pac J Cancer Prev, 14, 6427-31.
41. Zhou X, Zhao F, Wang ZN, Song YX, Chang H, Chiang Y, et al. (2012). Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation. Oncol Rep, 27, 447-54.
42. Zhu C, Li J, Ding Q, Cheng G, Zhou H, Tao L, et al. (2013). miR-152 controls migration and invasive potential by targeting TGFalpha in prostate cancer cell lines. The Prostate, 73, 1082-9.